News

In the competitive landscape of the global pharmaceutical industry, collaboration and consolidation often pave the way for success—especially for smaller companies aiming to make a significant impact. Pelthos Therapeutics, a Durham-based pharmaceutical firm and wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is taking a strategic step to strengthen its market position. The company is joining forces with Channel Therapeutics (NYSE American: CHRO) to support the commercial launch of its innovative prescription drug, ZELSUVMI, which received federal marketing approval last year. Discover how his partnership is designed to amplify Pelthos' capabilities and reach as it brings ZELSUVMI to market.